ATR 1072
PRKAG2 Syndrome
Pre-clinicalLead candidate; IND planned H2 2026
Key Facts
Indication
PRKAG2 Syndrome
Phase
Pre-clinical
Status
Lead candidate; IND planned H2 2026
Company
About Atrium Therapeutics
Atrium Therapeutics is a clinical-stage biotech focused on pioneering precision RNA medicines for the heart. The company emerged as a spinoff from Novartis's acquisition of Avidity Biosciences, launching with approximately $270 million to advance its novel cardiac-targeted AOC delivery platform. Its strategy is to address the high unmet need in rare genetic cardiomyopathies, with an IND filing for its lead candidate, ATR 1072, planned for H2 2026. Under CEO Kath Gallagher, Atrium combines deep RNA and rare disease expertise to transform cardiology from symptom management to curative genetic intervention.
View full company profile